MRI accurately identifies early murine mammary cancers and reliably differentiates between in situ and invasive cancer: Correlation of MRI with histology

NMR in Biomedicine

Volumn 28, Issue 9, 2015, Pages 1078-1086

  Mustafi, Devkumar ^a   Zamora, Marta ^a   Fan, Xiaobing ^a   Markiewicz, Erica ^a   Mueller, Jeffrey ^a   Conzen, Suzanne D ^a   Karczmar, Gregory S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Ductal carcinoma in situ (DCIS); Mammary intraepithelial neoplasia (MIN); Mouse mammary cancers; MRI histopathological correlation; Three dimensional MRI

Indexed keywords

DIAGNOSIS; GOLD; HISTOLOGY; MAGNETIC RESONANCE IMAGING; MAMMALS; MUSCLE;

DUCTAL CARCINOMA IN SITU; FAST SPIN ECHOS; GOLD STANDARDS; HIGH RESOLUTION; HUMAN BREAST CANCER; MAMMARY CANCER; MAMMARY INTRAEPITHELIAL NEOPLASIA (MIN); SIGNAL INTENSITIES;

DISEASES;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EX VIVO STUDY; FEMALE; GOLD STANDARD; HISTOPATHOLOGY; IN VIVO STUDY; INTERMETHOD COMPARISON; LYMPH NODE; MOUSE; MOUSE MODEL; MUSCLE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRIORITY JOURNAL; SIGNAL NOISE RATIO; THREE DIMENSIONAL IMAGING; TUMOR INVASION; ANIMAL; DISEASE MODEL; EXPERIMENTAL MAMMARY NEOPLASM; GENETICS; HUMAN; IMMUNOLOGY; INTRADUCTAL CARCINOMA; PATHOLOGY; PROCEDURES; SIMIAN VIRUS 40; TRANSGENIC MOUSE;

MURINAE; MUS;

VIRUS T ANTIGEN;

ANIMALS; ANTIGENS, POLYOMAVIRUS TRANSFORMING; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM INVASIVENESS; SIMIAN VIRUS 40;

EID: 84939265052     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3348     Document Type: Article

References (25)

1. Tillman GF, Orel SG, Schnall MD, Schultz DJ, Tan JE, Solin LJ. Effect of breast magnetic resonance imaging on the clinical management of women with early-stage breast carcinoma. J. Clin. Oncol. 2002; 20(16): 3413-3423.
2. Hylton N. Magnetic resonance imaging of the breast: opportunities to improve breast cancer management. J. Clin. Oncol. 2005; 23(8): 1678-1684.
3. Galinsky D, Kisselgoff D, Sella T, Peretz T, Libson E, Sklair-Levy M. Effect of breast magnetic resonance imaging on the clinical management of breast cancer. Isr. Med. Assoc. J. 2005; 7(11): 700-703.
4. Zakhireh J, Gomez R, Esserman L. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer. Eur. J. Cancer 2008; 44(18): 2742-2752.
5. Enriquez L, Listinsky J. Role of MRI in breast cancer management. Cleve. Clin. J. Med. 2009; 76(9): 525-532.
6. Scomersi S, Urbani M, Tonutti M, Zanconati F, Bortul M. Role of magnetic resonance imaging in managing selected women with newly diagnosed breast cancer. Breast 2010; 19(2): 115-119.
7. Pediconi F, Miglio E, Telesca M, Luciani ML, Kirchin MA, Passariello R, Catalano C. Effect of preoperative breast magnetic resonance imaging on surgical decision making and cancer recurrence rates. Invest. Radiol. 2012; 47(2): 128-135.
8. Duygulu G, Oktay A, Bilgen IG, Kapkac M, Zekioglu O. The role of breast MRI in planning the surgical treatment of breast cancer. Diagn. Interv. Radiol. 2012; 18(5): 460-467.
9. Yamaguchi K, Schacht D, Sennett CA, Newstead GM, Imaizumi T, Irie H, Abe H. Decision making for breast lesions initially detected at contrast-enhanced breast MRI. Am. J. Roentgenol. 2013; 201(6): 1376-1385.
10. Zuiani C, Francescutti GE, Londero V, Zunnui I, Bazzocchi M. Ductal carcinoma in situ: is there a role for MRI? J. Exp. Clin. Cancer Res. 2002; 21(3 Suppl): 89-95.
11. Mossa-Basha M, Fundaro GM, Shah BA, Ali S, Pantelic MV. Ductal carcinoma in situ of the breast: MR imaging findings with histopathologic correlation. Radiographics 2010; 30(6): 1673-1687.
12. Deurloo EE, Sriram JD, Teertstra HJ, Loo CE, Wesseling J, Rutgers EJ, Gilhuijs KG. MRI of the breast in patients with DCIS to exclude the presence of invasive disease. Eur. Radiol. 2012; 22(7): 1504-1511.
13. Pilewskie M, Kennedy C, Shappell C, Helenowski I, Scholtens D, Hansen N, Bethke K, Jeruss J, Karstaedt P, Khan SA. Effect of MRI on the management of ductal carcinoma in situ of the breast. Ann. Surg. Oncol. 2013; 20(5): 1522-1529.
14. Greenwood HI, Heller SL, Kim S, Sigmund EE, Shaylor SD, Moy L. Ductal carcinoma in situ of the breasts: review of MR imaging features. Radiographics 2013; 33(6): 1569-1588.
15. Jansen SA, Conzen SD, Fan X, Krausz T, Zamora M, Foxley S, River J, Newstead GM, Karczmar GS. Detection of in situ mammary cancer in a transgenic mouse model: in vitro and in vivo MRI studies demonstrate histopathologic correlation. Phys. Med. Biol. 2008; 53(19): 5481-5493.
16. Jansen SA, Conzen SD, Fan X, Markiewicz EJ, Newstead GM, Karczmar GS. Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study. Breast Cancer Res. 2009; 11(5): R65.
17. Jansen SA, Paunesku T, Fan X, Woloschak GE, Vogt S, Conzen SD, Krausz T, Newstead GM, Karczmar GS. Ductal carcinoma in situ: X-ray fluorescence microscopy and dynamic contrast-enhanced MR imaging reveals gadolinium uptake within neoplastic mammary ducts in a murine model. Radiology 2009; 253(2): 399-406.
18. Jansen SA, Fan X, Medved M, Abe H, Shimauchi A, Yang C, Zamora M, Foxley S, Olopade OI, Karczmar GS, Newstead GM. Characterizing early contrast uptake of ductal carcinoma in situ with high temporal resolution dynamic contrast-enhanced MRI of the breast: a pilot study. Phys. Med. Biol. 2010; 55(19): N473-N485.
19. Jansen SA, Conzen SD, Fan X, Markiewicz E, Krausz T, Newstead GM, Karczmar GS. In vivo MRI of early stage mammary cancers and the normal mouse mammary gland. NMR Biomed. 2011; 24(7): 880-887.
20. Maroulakou IG, Anver M, Garrett L, Green JE. Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. Proc. Natl. Acad. Sci. U. S. A. 1994; 91(23): 11236-11240.
21. Shibata MA, Maroulakou IG, Jorcyk CL, Gold LG, Ward JM, Green JE. p53-independent apoptosis during mammary tumor progression in C3(1)/SV40 large T antigen transgenic mice: suppression of apoptosis during the transition from preneoplasia to carcinoma. Cancer Res. 1996; 56(13): 2998-3003.
22. Cardiff RD, Anver MR, Gusterson BA, Hennighausen L, Jensen RA, Merino MJ, Rehm S, Russo J, Tavassoli FA, Wakefield LM, Ward JM, Green JE. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000; 19(8): 968-988.
23. Fan X, Mustafi D, Markiewicz E, Zamora M, Vosicky J, Leinroth A, Mueller J, Macleod K, Conzen SD, Karczmar GS. Mammary cancer initiation and progression studied with magnetic resonance imaging. Breast Cancer Res. 2014; 16(6): 495.
24. Xu J, Humphrey PA, Kibel AS, Snyder AZ, Narra VR, Ackerman JJ, Song SK. Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn. Reson. Med. 2009; 61(4): 842-850.
25. Hipp E, Fan X, Jansen SA, Markiewicz EJ, Vosicky J, Newstead GM, Conzen SD, Krausz T, Karczmar GS. T(2)* relaxation times of intraductal murine mammary cancer, invasive mammary cancer, and normal mammary gland. Med. Phys. 2012; 39(3): 1309-1313.